http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113952319-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa290cfbc4cd90be40bdc3dfa6829f54 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 |
| filingDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a27c73584c552a1efbf96ea8d4c7ce3c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3e5601d6c521fbcba0484f9e22ba6f7 |
| publicationDate | 2022-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113952319-A |
| titleOfInvention | A kind of skeleton type transdermal patch containing buprenorphine and preparation method thereof |
| abstract | The invention discloses a buprenorphine transdermal patch and a preparation method thereof. The buprenorphine transdermal patch can be continuously released to keep the blood drug concentration stable within the effective therapeutic concentration, avoid the peak-to-trough fluctuation of the blood drug concentration, reduce adverse reactions and enhance the analgesic effect. However, due to the barrier effect of the skin and the physical and chemical properties of buprenorphine, the permeability of buprenorphine on the skin is poor. In order to solve the problem of permeability, it is usually necessary to add a penetration enhancer to reduce the resistance of stratum corneum percutaneous penetration, but the patch structure is complex and the production cost is high; or it is necessary to expand the administration area to increase the degree of penetration, but at the same time increase the skin irritation. incidence rate. The currently marketed buprenorphine transdermal patches have complex structures and low availability of active ingredients. The buprenorphine transdermal patch disclosed by the invention has the advantages of simple structure, lower drug loading and less drug residue, can be continuously applied for 3 to 7 days, has a continuous and stable transdermal effect, and has good safety. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116098878-A |
| priorityDate | 2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.